Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Microcrystalline hydroxyapatite concentrate (MCHC) is a supplement derived from bovine bone and contains calcium, phosphorus, collagen, and various bone growth factors. Its use for osteoporosis is based on the rationale that it provides bone minerals in a form more similar to natural bone than standard calcium supplements. Several clinical studies have examined MCHC’s effects on bone health, with some suggesting a modest benefit in reducing bone loss compared to calcium carbonate or placebo. For instance, a few randomized controlled trials found that MCHC supplementation led to a slower rate of bone mineral density (BMD) loss in postmenopausal women, particularly when combined with vitamin D. However, these studies are generally small, of short duration, and sometimes sponsored by supplement manufacturers, limiting the strength of the evidence.

While MCHC has a long history of use in Europe for bone health, most major guidelines for osteoporosis management prioritize well-studied interventions such as bisphosphonates, denosumab, or calcium/vitamin D supplementation. There is insufficient robust evidence to recommend MCHC as a primary or stand-alone treatment for osteoporosis. Safety concerns also exist regarding possible contamination and variability in supplement quality. In summary, while there is some scientific rationale and limited clinical evidence for MCHC use in osteoporosis, the quality and quantity of data are not strong, and it should not replace established osteoporosis therapies.

More about microcrystalline hydroxyapatite concentrate (MCHC)
More about Osteoporosis

Other ingredients used for Osteoporosis

Other health conditions supported by microcrystalline hydroxyapatite concentrate (MCHC)

Products containing microcrystalline hydroxyapatite concentrate (MCHC)